- Home
- AMRX
as 03-28-2025 4:00pm EST
Amneal Pharmaceuticals Inc is a global pharmaceutical company operating primarily in the U.S., India, and Ireland. With three reportable segments; Generics, Specialty, and AvKARE - It develop, manufacture, and distribute a diverse portfolio of essential medicines. The Generics segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | N/A |
| Market Cap: | 2.4B | IPO Year: | N/A |
| Target Price: | $10.80 | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.38 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.18 - $9.48 | Next Earning Date: | 05-02-2025 |
| Revenue: | $2,793,957,000 | Revenue Growth: | 16.73% |
| Revenue Growth (this year): | 9.77% | Revenue Growth (next year): | 4.99% |
Stock Insider Trading Activity of Amneal Pharmaceuticals Inc. (AMRX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Patel Tushar Bhikhubhai | AMRX | 10% Owner | Mar 14 '25 | Sell | $8.35 | 5,000,000 | $41,750,000.00 | 48,578,209 | |
| Konidaris Tasos | AMRX | Executive Vice President & CFO | Mar 5 '25 | Sell | $8.91 | 100,000 | $891,000.00 | 621,882 | |
| BOYER ANDREW S | AMRX | Executive Vice President | Mar 5 '25 | Sell | $8.89 | 125,000 | $1,111,250.00 | 290,106 | |
| Alva Emily Peterson | AMRX | Director | Mar 5 '25 | Sell | $8.90 | 80,000 | $712,000.00 | 170,771 | |
| Daly Jason B. | AMRX | EVP, Chief Legal Officer | Mar 5 '25 | Sell | $8.81 | 90,000 | $792,159.60 | 32,606 | |
| Patel Gautam | AMRX | Director | Mar 3 '25 | Sell | $8.90 | 80,000 | $712,000.00 | 1,808,886 | |
| Patel Gautam | AMRX | Director | Feb 3 '25 | Sell | $8.14 | 80,000 | $651,200.00 | 1,808,886 | |
| Patel Gautam | AMRX | Director | Jan 8 '25 | Sell | $8.01 | 62,590 | $501,345.90 | 1,808,886 | |
| Patel Gautam | AMRX | Director | Jan 2 '25 | Sell | $8.01 | 17,410 | $139,454.10 | 1,808,886 |
Latest Amneal Pharmaceuticals Inc. News
AMRX Breaking Stock News: Dive into AMRX Ticker-Specific Updates for Smart Investing
Business Wire
19 days ago
Amneal to Participate at Upcoming Investor Conference
Business Wire
a month ago
Amneal’s BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA
Simply Wall St.
a month ago
Amneal Pharmaceuticals Full Year 2024 Earnings: EPS Misses Expectations
Business Wire
a month ago
Amneal Reports Fourth Quarter and Full Year 2024 Financial Results
GuruFocus.com
a month ago
Amneal Pharmaceuticals Inc (AMRX) Q4 2024: Everything You Need To Know Ahead Of Earnings
Business Wire
a month ago
Amneal Launches Mesalamine and Receives U.S. FDA Approval for Lenalidomide
Simply Wall St.
a month ago
Although Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) insiders have sold lately, they have the highest ownership with 51% stake
Clinical Trials Arena
2 months ago
7MM PD market to grow by $4.5bn between 2023 and 2033
Compare AMRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AMRX Amneal Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.